Lilly’s Imlunestrant Shows Breast Cancer Benefit With Verzenio In All Comers
A Phase III trial testing the oral SERD showed a PFS benefit in ER+/HER2- advanced breast cancer in combination with a CDK4/6 inhibitor regardless of mutation status.
A Phase III trial testing the oral SERD showed a PFS benefit in ER+/HER2- advanced breast cancer in combination with a CDK4/6 inhibitor regardless of mutation status.